SecBot SecBot
PRESS-RELEASE ·Filed Aug 12, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The primary catalyst is the CHAPTER-3 topline data expected in 3Q2026, which will determine the viability of deucrictibant XR for HAE prophylaxis. The FDA PDUFA date for deucrictibant IR is April 23, 2027. Monitor for CHAPTER-3 data release and any regulatory updates.

DirectionNeutral
Confidencemedium
Horizonweeks

deucrictibant

◆ Mixed Named in this press release
Impact
Phase
Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
Time to market
IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
Next catalyst
None dated

What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$36.46
T+0 close · Aug 12, 2026 · via day close
Latest settled
−5.84%
T+60 · $34.33
Vs SPY
−0.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $36.46entry
  2. T+1 · 3mo ago −6.64%α −7.34% · $34.04
  3. T+5 · 3mo ago −0.52%α −0.08% · $36.27
  4. T+20 · 2mo ago +2.88%α +4.78% · $37.51
  5. T+60 · 12d ago −5.84%α −0.97% · $34.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris reported Q2 2026 results with a loss per share of €0.70, slightly above the consensus EPS estimate of -$0.65 (per ADS) but the comparison is not directly comparable due to currency and share basis differences. The key event is the expected topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, which is the primary stock-moving catalyst.

Key Financial Metrics

EPS
−$0.70
Revenue
$0.00
est $0.00

Key Facts

  • Cash and cash equivalents of €318 million as of June 30, 2026, extending cash runway into 2028
  • Loss for Q2 2026 was €47.8 million, or €0.70 per share, vs €45.5 million (€0.83 per share) in Q2 2025
  • Topline data from CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis expected in 3Q2026
  • FDA accepted NDA for deucrictibant IR with PDUFA date of April 23, 2027; EMA validated MAA in July 2026
  • Closed $132.3 million underwritten offering in May 2026
  • R&D expenses increased to €35.0 million from €29.6 million YoY; G&A expenses rose to €15.8 million from €10.8 million

Financial Impact

No revenue; net loss of €47.8 million in Q2 2026; cash burn rate approximately €26 million per quarter (based on cash decrease from €292M to €318M, net of $132M offering proceeds)

cashr&d expensesnet loss

Risk Factors

  • CHAPTER-3 Phase 3 data may fail to meet primary endpoints, jeopardizing the prophylactic indication
  • FDA review of deucrictibant IR NDA could result in a Complete Response Letter or extended review
  • Pre-revenue biotech with no approved products; depends on successful clinical and regulatory outcomes
  • Currency mismatch: financials reported in EUR, consensus estimates in USD per ADS

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3343484

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026